Evidence map›Paper›PMID 36497391›Full record

ArticleCancers2022

Adrenomedullin Secreted by Melanoma Cells Promotes Melanoma Tumor Growth through Angiogenesis and Lymphangiogenesis.

Zohra Benyahia, Caroline Gaudy-Marqueste, Caroline Berenguer-Daizé, Norhimane Chabane, Nadège Dussault, Mylène Cayol, Christine Vellutini, Amina Djemli, Isabelle Nanni, Nathalie Beaufils and 3 more

Open access · goldAbstract read
In one paragraph

Article in Cancers, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
0.9field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 10 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Adrenomedullin in Tumorigenesis and Cancer Progression.International journal of molecular sciences · 2025
    Review
  5. Review
  6. Review
  7. Review
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 2 institutions in 1 country.

Zohra BenyahiaAix Marseille Univ, CNRS, INP, Inst Neurophysiopathol, 13005 Marseille, France.
Caroline Gaudy-MarquesteAix Marseille Univ, APHM, CHU Timone, Service de Dermatologie et de Cancérologie Cutanée, 13005 Marseille, France.
Caroline Berenguer-DaizéAix Marseille Univ, CNRS, INP, Inst Neurophysiopathol, 13005 Marseille, France.
Norhimane ChabaneAix Marseille Univ, CNRS, INP, Inst Neurophysiopathol, 13005 Marseille, France.
Nadège DussaultAix Marseille Univ, CNRS, INP, Inst Neurophysiopathol, 13005 Marseille, France.
Mylène CayolAix Marseille Univ, CNRS, INP, Inst Neurophysiopathol, 13005 Marseille, France.
Christine VellutiniAix Marseille Univ, CNRS, INP, Inst Neurophysiopathol, 13005 Marseille, France.
Amina DjemliAix Marseille Univ, APHM, CHU Nord, Service D'anatomopathologie, 13015 Marseille, France.ORCID 0000-0001-7287-4506
Isabelle NanniAix Marseille Univ, APHM, CHU Nord, Service D'Onco-Biologie, 13015 Marseille, France.
Nathalie BeaufilsAix Marseille Univ, APHM, CHU Nord, Service D'Onco-Biologie, 13015 Marseille, France.
Kamel MabroukAix Marseille Univ, CNRS, ICR, Institut de Chimie Radicalaire, 13013 Marseille, France.
Jean-Jacques GrobAix Marseille Univ, APHM, CHU Timone, Service de Dermatologie et de Cancérologie Cutanée, 13005 Marseille, France.ORCID 0000-0002-0667-153X
L'Houcine OuafikAix Marseille Univ, CNRS, INP, Inst Neurophysiopathol, 13005 Marseille, France.ORCID 0000-0002-4848-1232
Centre National de la Recherche Scientifique · FRAix-Marseille Université · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionMetastatic melanoma is an aggressive tumor and can constitute a real therapeutic challenge despite the significant progress achieved with targeted therapies and immunotherapies, thus highlighting the need for the identification of new therapeutic targets. Adrenomedullin (AM) is a peptide with significant expression in multiple types of tumors and is multifunctional. AM impacts angiogenesis and tumor growth and binds to calcitonin receptor-like receptor/receptor activity-modifying protein 2 or 3 (CLR/RAMP2; CLR/RAMP3).

methodsIn vitro and in vivo studies were performed to determine the functional role of AM in melanoma growth and tumor-associated angiogenesis and lymphangiogenesis.

resultsIn this study, AM and AM receptors were immunohistochemically localized in the tumoral compartment of melanoma tissue, suggesting that the AM system plays a role in melanoma growth. We used A375, SK-MEL-28, and MeWo cells, for which we demonstrate an expression of AM and its receptors; hypoxia induces the expression of AM in melanoma cells. The proliferation of A375 and SK-MEL-28 cells is decreased by anti-AM antibody (αAM) and anti-AMR antibodies (αAMR), supporting the fact that AM may function as a potent autocrine/paracrine growth factor for melanoma cells. Furthermore, migration and invasion of melanoma cells increased after treatment with AM and decreased after treatment with αAMR, thus indicating that melanoma cells are regulated by AM. Systemic administration of αAMR reduced neovascularization of in vivo Matrigel plugs containing melanoma cells, as demonstrated by reduced numbers of vessel structures, which suggests that AM is one of the melanoma cells-derived factors responsible for endothelial cell-like and pericyte recruitment in the construction of neovascularization. In vivo, αAMR therapy blocked angiogenesis and lymphangiogenesis and decreased proliferation in MeWo xenografts, thereby resulting in tumor regression. Histological examination of αAMR-treated tumors showed evidence of the disruption of tumor vascularity, with depletion of vascular endothelial cells and a significant decrease in lymphatic endothelial cells.

conclusionsThe expression of AM by melanoma cells promotes tumor growth and neovascularization by supplying/amplifying signals for neoangiogenesis and lymphangiogenesis.

Indexed as

A375adrenomedullinangiogenesisinvasionlymphangiogenesismelanomaMeWoSK-MEL-28tumor growth

Identifiers

PMID36497391
PMCPMC9738606
OpenAlexW4310623722

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.